Tissue confirmation of disease recurrence in breast cancer patients: pooled analysis of multi-centre, multi-disciplinary prospective studies.
about
Minimal residual disease in breast cancer: an overview of circulating and disseminated tumour cellsBiological markers of invasive breast cancerStathmin protein level, a potential predictive marker for taxane treatment response in endometrial cancerSystemic treatment approaches in her2-negative advanced breast cancer-guidance on the guidelinesESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)†Circulating Tumor Cell Isolation and Analysis.Pancreatic solitary and synchronous metastasis from breast cancer: a case report and systematic review of controversies in diagnosis and treatment.Sensitive capture of circulating tumour cells by functionalized graphene oxide nanosheets.Biopsy confirmation of metastatic sites in breast cancer patients: clinical impact and future perspectives.Discordances in estrogen receptor status, progesterone receptor status, and HER2 status between primary breast cancer and metastasis.Use of Biomarkers to Guide Decisions on Systemic Therapy for Women With Metastatic Breast Cancer: American Society of Clinical Oncology Clinical Practice GuidelineRecommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update.Development of circulating tumor cell-endocrine therapy index in patients with hormone receptor-positive breast cancer.The maximum standardized uptake value of 18 F-FDG PET scan to determine prognosis of hormone-receptor positive metastatic breast cancerCTC enumeration and characterization: moving toward personalized medicine.Metastatic progression of breast cancer: insights from 50 years of autopsies.The preliminary study of 16α-[18F]fluoroestradiol PET/CT in assisting the individualized treatment decisions of breast cancer patients.Endometrial Endometrioid Carcinoma Metastases Show Decreased ER-Alpha and PR-A Expression Compared to Matched Primary Tumors.Contribution of Estrone Sulfate to Cell Proliferation in Aromatase Inhibitor (AI) -Resistant, Hormone Receptor-Positive Breast Cancer.Comparison of the HER2, estrogen and progesterone receptor expression profile of primary tumor, metastases and circulating tumor cells in metastatic breast cancer patients.Biopsy of breast cancer metastases: patient characteristics and survivalHormone receptor status predicts the clinical outcome of human epidermal growth factor 2-positive metastatic breast cancer patients receiving trastuzumab therapy: a multicenter retrospective studyThe prognostic utility of the transcription factor SRF in docetaxel-resistant prostate cancer: in-vitro discovery and in-vivo validation.Metastatic gastric carcinoma from breast cancer mimicking primary linitis plastica: A case report.Conversion of epidermal growth factor receptor 2 and hormone receptor expression in breast cancer metastases to the brain.Breast cancer metastasis: issues for the personalization of its prevention and treatment.Appendicitis caused by the metastasis of HER2-positive breast cancer.Critical research gaps and translational priorities for the successful prevention and treatment of breast cancer.Prospective evaluation of the conversion rate in the receptor status between primary breast cancer and metastasis: results from the GEICAM 2009-03 ConvertHER study.Molecular Biomarkers for Prediction of Targeted Therapy Response in Metastatic Breast Cancer: Trick or Treat?Recent advances in the molecular characterization of circulating tumor cells.Developments in single photon emission computed tomography and PET-based HER2 molecular imaging for breast cancer.Biopsies: next-generation biospecimens for tailoring therapy.Latest biopsy approach for suspected metastases in patients with breast cancer.Discordance and clinical significance of ER, PR, and HER2 status between primary breast cancer and synchronous axillary lymph node metastasis.Systemic treatment of HER2+ metastatic breast cancer: clinical conundrums and future perspectives.Current status of molecular biomarkers in endometrial cancer.Challenges in the management of advanced, ER-positive, HER2-negative breast cancer.Histopathologic diagnosis of brain metastases: current trends in management and future considerations.Estrogen, progesterone, and HER2/neu receptor discordance between primary and metastatic breast tumours-a review.
P2860
Q26748850-3796C587-8452-42DE-A01B-D332C8DF2269Q26781177-483D22CE-C04E-4AD2-8631-6B32C3136FAEQ27852937-F069E4B7-C9E2-47DE-9C24-99977B738430Q28080469-D1F145D4-7E3A-4F59-9C19-1A2F1B91E4F1Q30317067-3DFE8962-A8BF-4305-A955-92E06A7C32D6Q30358229-C6F7A9EA-C36E-4E64-80F2-4A989B6C2C0FQ30725747-7423D3C1-FAE0-4311-A783-B3BCB8819E4CQ33597032-F8AABAD6-7974-4655-B6B1-C83A5BB7DFF4Q33738675-9148328D-FD4F-4CDB-9EA7-0878D4E4BEF9Q33777431-D0A07626-AA43-44AF-8BD6-670AB502D5F8Q33817285-17F8D214-0A2A-4A30-8840-5E8869F19610Q33862786-81DB52D5-2A5B-434B-881A-165B91CC4F2AQ33917455-0BFE4F65-CA0C-454E-8E8D-096C676B6056Q34569318-8766DC6B-F957-41E0-809B-2689011F13FCQ34577724-6CE228C6-92E8-483D-8ED4-8A72DCAC8436Q34891023-ACE4E244-9108-4CF7-87E0-63211DB31896Q35009047-A23999E7-3A92-4C13-A070-78521FC6F00FQ35739831-D948CEB3-1E62-4B25-B7A7-EAAF8208F120Q36030787-0B046B3E-6AC0-4E1B-AF17-2B801DDE9EF8Q36085375-D8C28B9C-BFD9-426C-AEC9-A9900A60F69DQ36239768-7054634B-5D99-4DF7-8D17-47AA9D21FC53Q36288976-DEB10003-BF0F-4F99-92CB-6D50A8C9CA3BQ36294460-14CCA293-704F-492F-AA2B-090E020EDD62Q36335765-AEE493EB-A2EF-4160-A1BB-EA8C33A71EC8Q36924473-14A65115-32C2-4A0D-BADB-57F62200788DQ37218214-75387021-D55A-4801-AF11-94219997F174Q37293067-D8E12167-D466-4946-B53E-17D5FC07D054Q37533025-69CA4204-F58A-4844-A966-51BC0FECB578Q37534923-7D223B18-39CB-4ED5-8508-B81C926941C8Q37631514-A26454FF-A86D-4F61-A2C9-86926F8CB5C2Q37693504-DC356037-BC54-4F84-B8DE-662716F41823Q38088005-55856C24-A40E-43CC-A44A-762454D0DEF7Q38116896-B6E47533-A265-4EBD-9323-53E6B11F5D3DQ38154494-DF6B1831-F6E7-495B-8983-C765FE31CC64Q38168792-E7FB98EC-0426-4193-9261-8993C1A56909Q38209464-6C55BCBC-D7B8-4A16-8967-F3C8042DF70AQ38234228-9809FF08-4F49-4BD2-86BC-AB481821CE3DQ38502890-D107CC28-497A-4F77-A001-D33DAE8928D9Q38791747-01BF2FE0-64FC-4FFE-A1D0-E01591CD3E6EQ38842674-EB05E0E3-5E12-4C2B-BCB0-19E8BDB09661
P2860
Tissue confirmation of disease recurrence in breast cancer patients: pooled analysis of multi-centre, multi-disciplinary prospective studies.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh
2011年學術文章
@zh-hant
name
Tissue confirmation of disease ...... ciplinary prospective studies.
@en
Tissue confirmation of disease ...... ciplinary prospective studies.
@nl
type
label
Tissue confirmation of disease ...... ciplinary prospective studies.
@en
Tissue confirmation of disease ...... ciplinary prospective studies.
@nl
prefLabel
Tissue confirmation of disease ...... ciplinary prospective studies.
@en
Tissue confirmation of disease ...... ciplinary prospective studies.
@nl
P2093
P50
P1476
Tissue confirmation of disease ...... ciplinary prospective studies.
@en
P2093
Alastair M Thompson
Lee B Jordan
Mark Clemons
Naomi Miller
Orit C Freedman
Robert E Coleman
William Geddie
P304
P356
10.1016/J.CTRV.2011.11.006
P577
2011-12-16T00:00:00Z